Niagen Bioscience, Inc.
Niagen Bioscience, Inc. (NAGE): 1 pipeline candidate · ~196 mo cash runway. Updated within the last hour.
BioSniper Score
4-factor signal · derived from public data
196.3 months
D/E 0.39 · 6% dilution
Lead: Preclinical
1 candidate
N/A
N/A
A transparent, data-derived signal for Niagen Bioscience, Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$273.2M
Cash
$66.5M
Quarterly Burn
$1.2M
Runway
196.3 mo
Revenue
$31.5M
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (1 candidate)
| Drug | Phase |
|---|---|
| niagen | Preclinical |
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
141
Total value held
$142.7M
| Holder | Shares | Value |
|---|---|---|
| vanguard capital management llc | 4,298,554 | $19.0M |
| blackrock, inc. | 3,871,619 | $17.1M |
| arrowstreet capital, limited partnership | 2,378,437 | $10.5M |
| geode capital management, llc | 1,344,921 | $5.9M |
| renaissance technologies llc | 1,328,843 | $5.9M |
| goldman sachs group inc | 1,251,959 | $5.5M |
| vanguard portfolio management llc | 1,221,494 | $5.4M |
| eversource wealth advisors, llc | 54,737 | $5.3M |
| state street corp | 1,084,565 | $4.8M |
| dimensional fund advisors lp | 1,071,133 | $4.7M |
Showing top 10 of 141 institutional holders of Niagen Bioscience, Inc.. Sign up for the full 13F holder list and quarter-by-quarter ownership history.
Frequently asked questions
How many drug candidates are in Niagen Bioscience, Inc.'s pipeline?
Niagen Bioscience, Inc. (NAGE) has 1 pipeline candidate tracked by BioSniper across SEC filings and clinical trial registrations.
What is Niagen Bioscience, Inc.'s lead drug candidate?
Niagen Bioscience, Inc.'s most advanced tracked candidate is niagen (Preclinical) for rare advanced aging diseases.
What is Niagen Bioscience, Inc.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, Niagen Bioscience, Inc. has approximately 196.3 months of cash runway.
What is Niagen Bioscience, Inc.'s market capitalization?
Niagen Bioscience, Inc.'s market capitalization is approximately $273.2M.
Who is the CEO of Niagen Bioscience, Inc.?
Mr. Robert N. Fried is the chief executive officer of Niagen Bioscience, Inc. (NAGE).
Get the full picture on Niagen Bioscience, Inc.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.